/** blogpostTitle: Viyash Q1 FY27: Margin Expansion, Debt Reduction, and a Companion Animal Push blogpostSlug: viyash-q1 blogpostCoverImageUrl: null blogpostCoverImageDescription: Ultra-realistic corporate finance scene: a clean desk with a laptop showing a professional dashboard featuring a rising revenue line from about 729 to 946 (in INR crore units), a bar chart highlighting EBITDA margin rising to about 21.6%, and a small gauge showing net debt to EBITDA near 0.1x. In the background, a subtle Europe map outline with Italy highlighted to reflect the Bio For Life acquisition theme. No logos or text labels. blogpostShortTitle: Viyash Q1 FY27 margins and deleveraging */

Viyash Q1 FY27: Margin Expansion, Debt Reduction, and a Companion Animal Push

Viyash Scientific Limited reported a strong start to FY27, with Q1 revenue from operations at INR 946.4 crore, up 19.5% year on year. Profitability moved faster than sales. Adjusted EBITDA (excluding ESOP costs) rose to INR 204.7 crore, up 59.2% year on year, and EBITDA margin expanded to 21.6% from 16.2% in Q1 FY26. Profit after tax came in at INR 79.3 crore versus INR 36.9 crore last year.

The quarter also reinforced a broader message from management: the integration work is largely complete, and the focus now is on operating leverage, disciplined execution, and selective strategic investments. This combination showed up in both the numbers and the strategic update around companion animals.

Profitability improved faster than revenue

Gross margin for the quarter was INR 512.1 crore, translating to a gross margin of 54.1% versus 51.9% a year ago. Operating costs were contained relative to growth, supporting EBITDA expansion. Finance cost reduced meaningfully, falling to INR 12.5 crore from INR 20.4 crore in Q1 FY26, which management linked to lower debt levels.

Balance sheet improvement is now a central part of the company’s narrative. Net debt reduced to INR 86.1 crore in Q1 FY27, taking net debt to LTM EBITDA down to 0.1x. Management contrasted this with about 1.0x a year earlier and 0.2x in Q4 FY26.

Note: Adjusted EBITDA is stated as EBITDA adjusted for ESOP costs in the investor presentation.

Segment performance: formulations led, APIs were stable

The company’s revenue split in the quarter showed formulations as the larger contributor.

Formulations revenue was INR 554.7 crore in Q1 FY27, up 33% year on year, while APIs were INR 383.3 crore, up 4% year on year. Within formulations, the geographic picture was constructive.

Europe formulations revenue was INR 184.7 crore, up 13% year on year. Emerging markets were INR 200.8 crore, up 36%. India was INR 43.0 crore, up 63%. USA formulations were INR 126.2 crore, up 60%.

The earnings call discussion clarified that Europe can look uneven across quarters due to contract phasing and market-level dynamics. Management suggested that the business should be assessed on a full-year basis, and reiterated an 18% to 20% growth expectation for Europe on an INR basis, while also noting that quarter three tends to be stronger.

US formulations were positioned as an outcome of a strategy shift. Management described the move of volume products to India, increased backward integration with in-house APIs, and a focus on more complex products as the drivers of both growth and margin improvement.

On APIs, management said Q1 was impacted by timing rather than demand loss. Customers delayed purchases due to raw material price volatility and uncertainty related to the ongoing war. Management’s view was that orders were returning in Q2 and that the API business could see a very strong quarter.

Companion animal strategy: Bio For Life in Italy

The most important strategic update was the acquisition announcement for Bio For Life in Italy. The company stated that it signed the SPA on 21 July 2026 and expects closing in September 2026.

In the investor presentation, Viyash highlighted four reasons for the acquisition: access to a large companion animal market in Italy, an existing companion portfolio of 85 to 90 products, the ability to launch the company’s global pipeline in Italy supported by a salesforce with about 85% vet clinic coverage, and a strong talent addition.

Management was measured when asked about near-term financial impact. They stated that using the platform to extend products into other countries requires registrations and approvals and typically takes around 18 to 24 months. In other words, this is not positioned as a one-year top-line accelerator. It is positioned as a market access and launch platform for Europe.

Investments and operating execution

Beyond M&A, the company highlighted operating execution in the quarter.

The business update section cited completion of 4 regulatory audits and 66 customer audits. It also listed approvals and activity across API and formulations, including 3 API regulatory approvals (USD MF, EDMF, CEP), 2 US FDF approvals, launches of 6 APIs and 4 FDF, and validations across 15 APIs and 4 FDF.

The R&D pipeline disclosed in the presentation was large in count terms: API 85+, Human FDF 24+, and Animal FDF 81+. Management also spoke about building high-potent oncology capabilities over the last two years and completing a high-potent formulation development lab, while emphasizing that meaningful revenue from some complex programs will be longer dated.

On capex, management mentioned an annual capex plan in the range of INR 250 to 300 crore. They also discussed companion animal tablet capacity expansion, with the project expected to start in the coming weeks and targeted readiness by January to February 2027 for exhibit batches.

ESOP costs and minority interests: what to watch

Two accounting and structure items stood out during the call.

First, ESOP costs. The investor presentation noted an increase in ESOP costs due to incremental grants linked to the amalgamation. The CFO guided that total ESOP cost for FY27 could be about INR 150 crore, and that this would reduce sharply in FY28 to around INR 25 to 30 crore.

Second, minority interest. Management stated that minority interests exist in two geographies, the US and Spain. The CFO indicated that minority interest has been around 16% to 17% of total profit in recent quarters, and investors should assume it stays in that range in the near term.

Takeaways

Q1 FY27 reinforced a combination of strong execution and improving financial structure. Revenue grew at a healthy pace, but margins expanded faster, and debt reduced further. The formulations business delivered broad-based geographic growth, while APIs were described as stable with timing-related softness expected to reverse.

Strategically, the Bio For Life acquisition is the clearest signal of where Viyash wants to invest next, building a companion animal platform with European market access. The timeline shared by management suggests that the operational and regulatory work following the acquisition will matter as much as the closing itself.

The next few quarters will test two things management emphasized: sustaining EBITDA margins in the 20% to 22% band, and converting a stronger balance sheet into disciplined organic and inorganic growth without losing the operational consistency that has underpinned the recent margin expansion.